Atacicept in Subjects With Active Lupus Nephritis (COMPASS) (COMPASS)
Lupus Nephritis (LN)
About this trial
This is an interventional treatment trial for Lupus Nephritis (LN) focused on measuring Systemic Lupus erythematosus (SLE), estimated glomerular filtration rate (eGFR), protenuria
Eligibility Criteria
Key Inclusion Criteria: Male or Female at least 18 years of age at time of signing consent Must have the ability to understand and sign and date a written informed consent form Diagnosis of SLE Biopsy- Proven Active LN Requires high-dose corticosteroids and immunosuppressive therapy for the treatment of active LN Subject is willing to take oral MMF for the duration of the study Key Exclusion Criteria: eGFR of ≤30 mL/min/1.73 m2. Sclerosis in 50% of glomeruli on renal biopsy. Evidence of rapidly progressive glomerulonephritis. Currently requiring renal dialysis or expected to require dialysis during the study. Serum igG <7 g/L Active infection or high infectious risk
Sites / Locations
- Vera Site # 0139
- Vera Site # 0138
- Vera Site # 0127
- Vera Site # 0129
- Vera Site # 0135
- Vera Site # 0136
- Vera Site # 0130
- Vera Site # 0131
- Vera Site # 0143
- Vera Site # 0140
- Vera Site # 0128
- Vera Site # 0134
- Vera Site # 0137
- Vera Site # 0144
- Vera Site # 0147
- Vera Site # 0109
- Vera Site # 0133
- Vera Site # 0149
- Vera Site # 0146
- Vera Site # 0142
- Vera Site # 0148
- Vera Site # 0145
- Vera SIte # 0132
- Vera Site # 0125
- Vera Site # 0126
- Vera Site # 0122
- Vera Site # 0141
- Vera Site # 0348
- Vera Site # 0347
- Vera Site # 0349
- Vera Site #0351
- Vera Site # 0350
- Vera Site # 0346
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Atacicept Dose
Placebo to match Atacicept
Atacicept Dose once weekly subcutaneous (SC) Injection
Placebo to match Atacicept once weekly subcutaneous (SC) injection